BRAF V600E positive papillary thyroid carcinoma (TERT and TP53 mutation coexistence excluded): Correlation of clinicopathological features and the extent of surgical treatment and its complications

HLOZEK, Jiri; Jan ROTNAGL; Richard HOLY; Tereza HLOŽKOVÁ; Barbora PEKOVA BULANOVA; Vlasta KUKLIKOVA; Bela BENDLOVA; Jiri SOUKUP; Petr HRABAL a Jaromir ASTL. BRAF V600E positive papillary thyroid carcinoma (TERT and TP53 mutation coexistence excluded): Correlation of clinicopathological features and the extent of surgical treatment and its complications. Journal of applied biomedicine. České Budějovice: Faculty of Health and Social Care, University of South Bohemia, 2024, roč. 22, č. 4, s. 214-220. ISSN 1214-021X. Dostupné z: https://doi.org/10.32725/jab.2024.025.

Základní údaje

Originální název

BRAF V600E positive papillary thyroid carcinoma (TERT and TP53 mutation coexistence excluded): Correlation of clinicopathological features and the extent of surgical treatment and its complications

Autoři

HLOZEK, Jiri; Jan ROTNAGL; Richard HOLY; Tereza HLOŽKOVÁ; Barbora PEKOVA BULANOVA; Vlasta KUKLIKOVA; Bela BENDLOVA; Jiri SOUKUP; Petr HRABAL a Jaromir ASTL

Vydání

Journal of applied biomedicine, České Budějovice, Faculty of Health and Social Care, University of South Bohemia, 2024, 1214-021X

---

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30212 Surgery

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.000

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00138800

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.32725/jab.2024.025

UT WoS

001375637400001

EID Scopus

2-s2.0-85214782524

Klíčová slova anglicky

BRAF V600E; Cancer; Clinicopathologic features; Complications; Mutation; Papillary Thyroid Carcinoma (PTC); Surgery; TERT; Thyroid

Štítky

14110126, rivok

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

Introduction: Papillary thyroid carcinoma (PTC) frequently harbors the BRAF V600E mutation. Recent research suggests that aggressive behavior in BRAF V600E+ PTC may be due to an undetected mutation in the TERT gene. This study aims to observe the clinicopathological features of BRAF V600+ PTC and correlate them with surgical treatment complications. Methods: A retrospective analysis was conducted on the BRAF V600E+ PTC cohort from July 2019 to January 2023. The histopathological features and surgical treatment (total thyroidectomy - group A, total thyroidectomy + central block neck dissection - group B) complications were correlated. Patients with TERT and TP53 mutation were excluded. Next-generation sequencing and real-time PCR were used for genetic analysis. Results: Out of 121 PTCs, 65 cases showed BRAF V600E mutation with the following features: intracapsular spread (13.8%), extracapsular spread (27.7%), extrathyroidal spread (15.4%), multifocality (26.2%), angioinvasion (12.3%), and local metastasis (27.7%). The incidence of surgical complications in group A/B was: reversible recurrent laryngeal nerve (RLN) paresis 3.7/7.1%, RLN paresis permanent 0/2.4%, paresthesia 6.8/23.8%, hypocalcemia 36.4/61.9% on day 1 and 27.3/33.3% on day 3, and bleeding 2.3/9.5%. There was no significant difference in clinicopathological features between the BRAF V600E+ and BRAF V600E- PTC groups. Group B had a significantly higher incidence of hypoacalcaemia on postoperative day 1 (p = 0.047). Conclusion: The BRAF V600E mutation will certainly remain important in the preoperative diagnosis of PTC. The more radical surgical procedures currently recommended may be abandoned in the future, particularly elective CLND, which has a higher risk of postoperative complications.